STPharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
STPharma
Largest movements
- Cash -€11,166
down €11,166 (-43.0%), from €25,954 to €14,788
mainly Receivables within one year (-€6,520) and Trade debts (-€3,893)
- Receivables within one year +€6,520
up €6,520 (+232%), from €2,807 to €9,327
of which Trade receivables: +€4,716
- Stocks and contracts +€2,264
new in 2025: €2,264
- Intangible fixed assets -€1,595
down €1,595 (-24.1%), from €6,622 to €5,027
- Trade debts -€3,893
down €3,893 (-49.4%), from €7,884 to €3,992
- Tax, wage and social debts -€732
down €732 (-82.1%), from €892 to €160
- Profit (loss) carried forward +€635
up €635 (+49.3%), from €1,287 to €1,922
- Gross operating margin -€2,695
down €2,695 (-45.5%), from €5,924 to €3,229
- Depreciation -€1,016
down €1,016 (-38.9%), from €2,611 to €1,595
- Other operating charges -€587
down €587 (-41.8%), from €1,405 to €817
- Taxes -€463
down €463 (-92.6%), from €500 to €37
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €35,383 | €31,406 | -€3,977 | -11.2% |
| Fixed assets | 21/28 | €6,622 | €5,027 | -€1,595 | -24.1% |
| Intangible fixed assets | 21 | €6,622 | €5,027 | -€1,595 | -24.1% |
| Current assets | 29/58 | €28,761 | €26,379 | -€2,382 | -8.3% |
| Stocks and contracts in progress | 3 | - | €2,264 | +€2,264 | |
| Stocks | 30/36 | - | €2,264 | +€2,264 | |
| Amounts receivable within one year | 40/41 | €2,807 | €9,327 | +€6,520 | +232% |
| Trade receivables | 40 | €2,684 | €7,399 | +€4,716 | +176% |
| Other amounts receivable | 41 | €124 | €1,928 | +€1,804 | +1,456% |
| Cash at bank and in hand | 54/58 | €25,954 | €14,788 | -€11,166 | -43.0% |
| Total equity and liabilities | 10/49 | €35,383 | €31,406 | -€3,977 | -11.2% |
| Equity | 10/15 | €26,287 | €26,922 | +€635 | +2.4% |
| Contributions | 10/11 | €25,000 | €25,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €1,287 | €1,922 | +€635 | +49.3% |
| Amounts payable | 17/49 | €9,096 | €4,485 | -€4,612 | -50.7% |
| Amounts payable within one year | 42/48 | €8,776 | €4,152 | -€4,625 | -52.7% |
| Trade debts | 44 | €7,884 | €3,992 | -€3,893 | -49.4% |
| Suppliers | 440/4 | €7,884 | €3,992 | -€3,893 | -49.4% |
| Taxes, remuneration and social security | 45 | €892 | €160 | -€732 | -82.1% |
| Taxes | 450/3 | €892 | €160 | -€732 | -82.1% |
| Accrued charges and deferred income | 492/3 | €320 | €333 | +€13 | +4.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,611 | €1,595 | -€1,016 | -38.9% |
| Other operating charges | 640/8 | €1,405 | €817 | -€587 | -41.8% |
| Gross operating margin | 9900 | €5,924 | €3,229 | -€2,695 | -45.5% |
| Operating profit (loss) | 9901 | €1,908 | €816 | -€1,092 | -57.2% |
| Financial income | 75/76B | - | €13 | +€13 | |
| Recurring financial income | 75 | - | €13 | +€13 | |
| Financial charges | 65/66B | €121 | €158 | +€36 | +30.0% |
| Recurring financial charges | 65 | €121 | €158 | +€36 | +30.0% |
| Profit (loss) for the period before taxes | 9903 | €1,787 | €672 | -€1,115 | -62.4% |
| Income taxes | 67/77 | €500 | €37 | -€463 | -92.6% |
| Profit (loss) for the period | 9904 | €1,287 | €635 | -€652 | -50.7% |
| Profit (loss) for the period to be appropriated | 9905 | €1,287 | €635 | -€652 | -50.7% |
Source: filed annual accounts (NBB), financial years ended 31 October 2024 and 31 October 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 25 October 2026 via checked.be.